Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

2

Revenue 2017

Revlimid

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Revlimid was produced by Celgene.

ASH18: CAR-T and drugs give new options for multiple myeloma

ASH18: CAR-T and drugs give new options for multiple myeloma Ninlaro is already approved as a second-line therapy in combination with Celgene’s Revlimid (lenalidomide) and dexamethasone, and Takeda is also trying to move its drug into the first-line

FDA green lights BMS’ multiple myeloma combo

FDA green lights BMS’ multiple myeloma combo That particular regimen also includes corticosteroid medication dexamethasone and Celgene’s blockbuster Revlimid, which generated around $8bn in sales last year.

FDA clears first-line use for J&J’s myeloma drug Darzalex

FDA clears first-line use for J&J’s myeloma drug Darzalex Later on, additional studies of Darzalex as an add-on to regimens based on Celgene’s Revlimid (lenalidomide) and in ASCT-eligible patients could further expand the opportunity in previously-untreated

Celgene to launch five new products through to 2020

Celgene to launch five new products through to 2020 The statements came as Celgene reported expectation-topping sales and earnings driven by Revlimid (lenalidomide) and new psoriasis therapy Otezla (apremilast). ... For comparison, Revlimid sales are expected to come in at around $9.7bn this year.

Chinese biotech’s global ambitions

Chinese biotech’s global ambitions Meanwhile, BeiGene entered into a strategic global collaboration with Celgene in 2017, gaining the rights to Celgene’s Abraxane Revlimid and Vidaza in China, while Celgene gained an option to market

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics